Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Century TherapeuticsIPSC +4.39%46 Debt-to-Equity is 0.18 as of Mar. 2026, which is at its 10-year median of 0.18. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $39.10 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 966 Biotechnology companies, Century Therapeutics ranks worse than 51.55% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Century Therapeutics's Debt-to-Equity or its related term are showing as below:
IPSC'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.27 Med: 0.18 Max: 0.33
Current: 0.18
During the past 7 years, the highest Debt-to-Equity Ratio of Century Therapeutics was 0.33. The lowest was -0.27. And the median was 0.18.
IPSC's Debt-to-Equity is ranked worse than 51.55% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs IPSC: 0.18
Century Therapeutics (NAS:IPSC) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Century Therapeutics Debt-to-Equity Related Terms
Century Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Century Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPSC vs PBYI, BNTC, ENTA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Century Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Century Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Century Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Century Therapeutics (IPSC) has a Debt-to-Equity of 0.18 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Century Therapeutics and its competitors. This is near median its historical median of 0.18. According to the industry distribution chart, Century Therapeutics ranks #498 out of 966 companies in the Biotechnology industry, placing it in the top 51.6%.
Is Century Therapeutics' Debt-to-Equity too high?
Century Therapeutics' current Debt-to-Equity of 0.18 is near median its 10-year median of 0.18. The Biotechnology industry median Debt-to-Equity is 0.16. Century Therapeutics' value of 0.18 is 12.5% above this industry median. Based on the distribution chart, Century Therapeutics ranks #498 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Debt-to-Equity compare to PBYI and BNTC?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #498 out of 966 companies for Debt-to-Equity. This places Century Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Century Therapeutics' value of 0.18 is 12.5% above this benchmark. While the company's 10-year median is 0.18 vs. the industry median of 0.16, Century Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Century Therapeutics's current Debt-to-Equity of 0.18 is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Century Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Century Therapeutics's current Debt-to-Equity is 0.18, which is near median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $39.10, compared to a current price of $2.26 — trading 94.2% below its estimated fair value. The current Debt-to-Equity is 0.18, which is near median its 10-year median of 0.18 and 12.5% above the Biotechnology industry median of 0.16. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Debt-to-Equity is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Century Therapeutics (IPSC) Overvalued in 2026?
Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued.
The current stock price of $2.26 is trading 94.2% below its estimated GF Value™ of $39.10.
GuruFocus considers Century Therapeutics to be Possible Value Trap.
Key valuation signals for IPSC:
Debt-to-Equity: 0.18 (near median its 10-year median of 0.18)
GF Value™: $39.10 vs. price of $2.26 (94.2% below fair value)
Industry Position: 12.5% above the Biotechnology median (#498 of 966)
No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score
Get the complete analysis for IPSC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSC has been successfully added to your 
